论文部分内容阅读
目的探讨益气补肾方在中晚期恶性肿瘤化疗患者中的应用及对其生活质量和细胞免疫功能的影响。方法选取2014年3月至2016年3月收治的中晚期恶性肿瘤化疗患者共120例,以随机数字表法分为对照组和观察组,每组60例。对照组患者给予常规化疗方案(肺癌TP方案,胃癌FAM方案,结直肠癌FL方案,乳腺癌TAC方案)~+对症支持干预;观察组患者则在此基础上加用益气补肾方辅助治疗;两组治疗时间均为18周。观察两组临床疗效、治疗前后中医证候积分、QLQ-C30量表评分、CD3~+、CD4~+、CD8~+、CD4~+/CD8~+、自然杀伤细胞(NK)水平及毒副反应发生率等的差异。结果观察组患者客观缓解率和临床受益率均显著高于对照组(P<0.05,P<0.01);两组治疗后中医证候积分均显著降低,且观察组患者治疗后低于对照组(P均<0.05);两组治疗后QLQ-C30量表评分均显著提高,且观察组患者治疗后高于对照组(P均<0.05);观察组患者治疗后CD3~+、CD4~+、CD4~+/CD8~+及NK细胞水平较对照组显著提高(P均<0.05),而CD8~+水平则显著降低(P<0.05);观察组毒副反应发生率显著低于对照组(P<0.05,P<0.01)。结论益气补肾方用于中晚期恶性肿瘤化疗患者的治疗,可有效延缓病情进展,缓解临床症状,提高日常生活质量,改善免疫系统功能,降低药物毒副反应发生的风险。
Objective To investigate the application of Yiqi Bushen Decoction in the treatment of advanced malignant tumor patients and its impact on the quality of life and cellular immune function. Methods A total of 120 patients with advanced malignant neoplasm who received chemotherapy from March 2014 to March 2016 were randomly divided into control group and observation group with 60 cases in each group. Patients in the control group received conventional chemotherapy (TP regimen of lung cancer, FAM regimen of gastric cancer, FL regimen of colorectal cancer, and TAC regimen of breast cancer) to + symptomatic supportive intervention. Patients in the observation group received adjuvant therapy with “Qi Tonifying Kidney” The treatment time was 18 weeks. The clinical curative effect, TCM Syndrome score before and after treatment, QLQ-C30 scale, CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, NK cells and toxicity The incidence of reaction and other differences. Results The objective remission rate and clinical benefit rate in the observation group were significantly higher than those in the control group (P <0.05, P <0.01). The scores of TCM syndromes in both groups were significantly decreased after treatment, and the observation group was lower than the control group P <0.05). The scores of QLQ-C30 in both groups were significantly increased after treatment, and the patients in the observation group were significantly higher than those in the control group after treatment (P <0.05) (P <0.05), while the level of CD8 ~ + was significantly lower (P <0.05). The incidence of toxic and side reactions in the observation group was significantly lower than that in the control group P <0.05, P <0.01). Conclusion Yiqi Bu Shen Decoction for the treatment of patients with advanced malignant tumor chemotherapy can effectively delay the progression of the disease, relieve clinical symptoms, improve the quality of daily life, improve the immune system, reduce the risk of drug toxicity.